Hypera S.A. (BVMF:HYPE3)

Market Cap	14.79B +17.5%
Revenue (ttm)	7.70B +3.4%
Net Income	1.20B -10.9%
EPS	1.88 -10.7%
Shares Out	632.95M
PE Ratio	12.44
Forward PE	8.43
Dividend	1.17 (5.01%)
Ex-Dividend Date	Apr 1, 2026

Volume	8,325,100
Average Volume	3,372,850
Open	23.55
Previous Close	23.37
Day's Range	23.50 - 23.89
52-Week Range	19.50 - 28.87
Beta	0.17
RSI	54.66
Earnings Date	Apr 28, 2026

About Hypera

Hypera S.A. operates as a pharmaceutical company in Brazil. The company provides sweeteners products under the Adocyl, finn, and Zero-cal brands; analgesics and anti-inflammatories products under the Doril, Atroveran, Calminex, Alivium, Buscopan, Buscofem, geloll, Torsilax, Neosaldina, and naprohax brands; cold and flu remedies and decongestants products under BENEGRIO, Rinosoro, Blu, Neosoro, Coristina, APRACUR, and Fluviral brands. It offers antihistamines products under Alektos, Histamin, Polaramine, PredSim, and Desrinite brands; antiseptic...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1999
• Employees: 10,564
• Stock Exchange: Brazil Stock Exchange
• Ticker Symbol: HYPE3

Financial Performance

In 2025, Hypera's revenue was 7.70 billion, an increase of 3.45% compared to the previous year's 7.44 billion. Earnings were 1.20 billion, a decrease of -10.86%.